Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma

Igor Puzanov, MD
Published: Tuesday, Dec 27, 2016



Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.

One of the most developed combinations is the CTLA-4 inhibitor ipilimumab (Yervoy) plus the PD-1 inhibitor nivolumab (Opdivo), which has been FDA approved for patients with melanoma. The combination has also been explored in these patients who have brain metastases, and it is shown to elicit clinical activity.

Additionally, an Eastern Cooperative Group study is exploring the sequence of BRAF inhibitors plus MEK inhibitors or immunotherapy in BRAF-positive patients in the frontline setting. Patients will undergo a 1:1 randomization for which treatment they will receive first, and then will switch treatments upon disease progression.
 


Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.

One of the most developed combinations is the CTLA-4 inhibitor ipilimumab (Yervoy) plus the PD-1 inhibitor nivolumab (Opdivo), which has been FDA approved for patients with melanoma. The combination has also been explored in these patients who have brain metastases, and it is shown to elicit clinical activity.

Additionally, an Eastern Cooperative Group study is exploring the sequence of BRAF inhibitors plus MEK inhibitors or immunotherapy in BRAF-positive patients in the frontline setting. Patients will undergo a 1:1 randomization for which treatment they will receive first, and then will switch treatments upon disease progression.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x